United Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
United Therapeutics has a total shareholder equity of $7.2B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $7.9B and $734.4M respectively. United Therapeutics's EBIT is $1.5B making its interest coverage ratio -8.9. It has cash and short-term investments of $3.0B.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -8.9x |
| Cash | US$3.05b |
| Equity | US$7.17b |
| Total liabilities | US$734.40m |
| Total assets | US$7.91b |
Recent financial health updates
Does United Therapeutics (NASDAQ:UTHR) Have A Healthy Balance Sheet?
May 11
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Feb 05Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18Recent updates
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Jul 22United Therapeutics: A Cheap But Complicated Tale
Jun 06Does United Therapeutics (NASDAQ:UTHR) Have A Healthy Balance Sheet?
May 11Investors Aren't Buying United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Apr 23Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Apr 05United Therapeutics: A Unique Business With High Margins And Expansion Potential
Feb 25Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Feb 05United Therapeutics Corporation (NASDAQ:UTHR) Doing What It Can To Lift Shares
Jan 18With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Dec 10United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27
Innovative Biotech Products Pave The Way For A Future Revenue Surge And Market Leadership
Advancements in treatments for pulmonary hypertension and fibrosis, and pioneering Xenotransplantation products, promise to lead market growth and address unmet medical needs.United Therapeutics: Economics Support Compounding Ability
Aug 20United Therapeutics: Exciting Company With A Big Problem
Jun 02United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Financial Position Analysis
Short Term Liabilities: UTHR's short term assets ($3.8B) exceed its short term liabilities ($527.1M).
Long Term Liabilities: UTHR's short term assets ($3.8B) exceed its long term liabilities ($207.3M).
Debt to Equity History and Analysis
Debt Level: UTHR is debt free.
Reducing Debt: UTHR has no debt compared to 5 years ago when its debt to equity ratio was 25.9%.
Debt Coverage: UTHR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: UTHR has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/18 16:06 |
| End of Day Share Price | 2025/08/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
United Therapeutics Corporation is covered by 35 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Birchenough | Barclays |
| Derek Taller | Benchmark Company |